Abstract
Introduction: Parthenogenetic chimera is an extremely rare condition in human. Very few patients with parthenogenetic chimerism with XX/XY cells have been identified. Case Presentation: We report the clinical findings and molecular analysis of chimerism with a 46,XX/46,XY karyotype in a patient presenting idiopathic oligoasthenoteratozoospermia (OAT). To clarify the mechanism of chimera formation, short tandem repeat analysis using 21 loci was carried out. Quantitation of alleles in D6S1043, D12S391, fibrinogen alpha chain, and amelogenin revealed double paternal and one maternal genetic contribution to the patient, which is consistent with a parthenogenetic chimerism. The likely mechanism of chimerism formation was also discussed, followed by a literature review. Conclusion: This is the first documented case of parthenogenetic chimerism in an adult male with XX/XY cells presenting OAT. Improved cell sampling and more sensitive and specific detection methods are necessary to identify more patients with XX/XY chimerism for systematic studies on this condition in the future.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Gartler
SM
, Waxman
SH
, Giblett
E
. An XX/XY human hermaphrodite resulting from double fertilization
. Proc Natl Acad Sci U S A
. 1962
;48
(3
):332
–5
. 2.
Malan
V
, Vekemans
M
, Turleau
C
. Chimera and other fertilization errors
. Clin Genet
. 2006
;70
(5
):363
–73
. 3.
Yu
N
, Kruskall
MS
, Yunis
JJ
, Knoll
JH
, Uhl
L
, Alosco
S
, et al. Disputed maternity leading to identification of tetragametic chimerism
. N Engl J Med
. 2002
;346
(20
):1545
–52
. 4.
Strain
L
, Warner
JP
, Johnston
T
, Bonthron
DT
. A human parthenogenetic chimaera
. Nat Genet
. 1995
;11
(2
):164
–9
. 5.
Giltay
JC
, Brunt
T
, Beemer
FA
, Wit
JM
, van Amstel
HK
, Pearson
PL
, et al. Polymorphic detection of a parthenogenetic maternal and double paternal contribution to a 46,XX/46,XY hermaphrodite
. Am J Hum Genet
. 1998
;62
(4
):937
–40
. 6.
Chen
CP
, Chern
SR
, Sheu
JC
, Lin
SP
, Hsu
CY
, Chang
TY
, et al. Prenatal diagnosis, sonographic findings and molecular genetic analysis of a 46,XX/46,XY true hermaphrodite chimera
. Prenat Diagn
. 2005
;25
(6
):502
–6
. 7.
Conlin
LK
, Thiel
BD
, Bonnemann
CG
, Medne
L
, Ernst
LM
, Zackai
EH
, et al. Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis
. Hum Mol Genet
. 2010
;19
(7
):1263
–75
. 8.
Shin
SY
, Yoo
HW
, Lee
BH
, Kim
KS
, Seo
EJ
. Identification of the mechanism underlying a human chimera by SNP array analysis
. Am J Med Genet
. 2012
;158A
(9
):2119
–23
. 9.
Xia
XY
, Wang
WP
, Li
TF
, Li
WW
, Wu
QY
, Li
N
, et al. A parthenogenetic maternal and double paternal contribution to an ovotesticular disorder of sex development
. Mol Cytogenet
. 2014
;7
(1
):16
. 10.
Kawamura
R
, Kato
T
, Miyai
S
, Suzuki
F
, Naru
Y
, Kato
M
, et al. A case of a parthenogenetic 46,XX/46,XY chimera presenting ambiguous genitalia
. J Hum Genet
. 2020
;65
(8
):705
–9
. 11.
Makrydimas
G
, Sebire
NJ
, Thornton
SE
, Zagorianakou
N
, Lolis
D
, Fisher
RA
. Complete hydatidiform mole and normal live birth: a novel case of confined placental mosaicism: case report
. Hum Reprod
. 2002
;17
(9
):2459
–63
. 12.
Winberg
J
, Gustavsson
P
, Lagerstedt-Robinson
K
, Blennow
E
, Lundin
J
, Iwarsson
E
, et al. Chimerism resulting from parthenogenetic activation and dispermic fertilization
. Am J Med Genet
. 2010
;152A
(9
):2277
–86
. 13.
Lee
KF
, Hsu
CS
, Kuo
PL
, Chen
JL
, Jiang
YH
, Liu
IY
. The identification of a spontaneous 47, XX, +21/46, XY chimeric fetus with male genitalia
. BMC Med Genet
. 2012
;13
:85
. 14.
Yamazawa
K
, Nakabayashi
K
, Kagami
M
, Sato
T
, Saitoh
S
, Horikawa
R
, et al. Parthenogenetic chimaerism/mosaicism with a Silver-Russell syndrome-like phenotype
. J Med Genet
. 2010
;47
(11
):782
–5
. 15.
World Health Organization
. WHO laboratory manual for the examination and processing of human semen
. 5th ed.Geneva
; 2010
.16.
McGowan-Jordan
J
, Hastings
RJ
, Moore
S
, editors. ISCN 2020: an international system for human cytogenomic nomenclature
. Basel
: Karger
; 2020
.17.
Krausz
C
, Navarro-Costa
P
, Wilke
M
, Tüttelmann
F
. EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state of the art 2023
. Andrology
. 2024
;12
(3
):487
–504
. 18.
Carrel
L
, Willard
HF
. X-inactivation profile reveals extensive variability in X-linked gene expression in females
. Nature
. 2005
;434
(7031
):400
–4
. 19.
Arnold
AP
, Chen
X
, Itoh
Y
. What a difference an X or Y makes: sex chromosomes, gene dose, and epigenetics in sexual differentiation
. Handb Exp Pharmacol
. 2012
;214
:67
–88
. 20.
James
PA
, Rose
K
, Francis
D
, Norris
F
. High-level 46XX/46XY chimerism without clinical effect in a healthy multiparous female
. Am J Med Genet
. 2011
;155A
(10
):2484
–8
. 21.
Kasami
M
, Yoshida
M
, Isogaki
J
, Ogawa
H
, Shinmura
K
, Endo
Y
, et al. Bilateral breast tumors, malignant phyllodes tumor and invasive lobular carcinoma in a 46,XX/46,XY mosaic female with family history of breast cancer
. Pathol Int
. 1997
;47
(2–3
):147
–54
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
